Carlsmed (NASDAQ: CARL) shares Q2 2025 results in Form 8-K filing

Rhea-AI Filing Summary

Carlsmed, Inc. filed a current report to disclose that it has released its financial results for the quarter ended June 30, 2025. On August 28, 2025, the company issued a press release with these quarterly results, which is included as Exhibit 99.1 to the report.

The press release describing the quarter’s results is being furnished rather than filed, meaning it is not automatically subject to certain liability provisions and is not automatically incorporated into other securities filings unless specifically referenced. The company’s common stock, with a par value of $0.00001 per share, trades on The Nasdaq Stock Market LLC under the symbol CARL.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001794546false00017945462025-08-282025-08-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2025

Carlsmed, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42756	83-1081863
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1800 Aston Ave, Suite 100
Carlsbad, California				92008
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (760) 766-1923

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		CARL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On August 28, 2025, the Company issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(a) Exhibits

Exhibit No.		Description
99.1*		Press Release of Carlsmed, Inc., dated August 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CARLSMED, INC.
Date: August 28, 2025	By:	/s/Michael Cordonnier
		Michael Cordonnier Chief Executive Officer and President

FAQ

What did Carlsmed (CARL) report in this Form 8-K?

Carlsmed, Inc. reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025, furnished as Exhibit 99.1.

When did Carlsmed (CARL) release its quarterly financial results?

Carlsmed released its quarterly financial results in a press release dated August 28, 2025, which is referenced in this Form 8-K under Item 2.02.

Which period do the reported Carlsmed (CARL) results cover?

The financial results discussed in the press release relate to Carlsmed’s quarter ended June 30, 2025.

How is the Carlsmed (CARL) earnings press release treated legally in this filing?

The information in Item 2.02, including Exhibit 99.1, is being furnished, not filed, so it is not deemed filed under Section 18 of the Exchange Act or automatically incorporated into Securities Act filings unless specifically referenced.

Where can investors find the detailed Carlsmed (CARL) quarterly results?

The detailed quarterly financial results are contained in Carlsmed’s press release furnished as Exhibit 99.1 to this Form 8-K.

On which exchange is Carlsmed (CARL) common stock listed?

Carlsmed’s common stock, par value $0.00001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol CARL.